We develop groundbreaking solutions for the detection of heart diseases. Juuso Blomster, CEO, Simonen (Communications) tel. Results from clinical multicenter studies in detection of heart failure and coronary artery disease are published later in 2022. Later, technological capabilities are expected to expand to other major heart diseases. We are pleased to introduce a truly novel solution that puts actionable clinical insights, and a near limitless range of digital capabilities for patient care, in the palms of their hands.”Īt first, the CardioSignal technology enables efficient atrial fibrillation screening. “Our commitment is to equip them with high-performance innovations that represent a real step change in their working lives. “Frontline health workers are under increasing pressure to not only accurately diagnose patients, but also make appropriate decisions on all aspects of disease management and patient care,” says Thomas Schinecker, CEO, Roche Diagnostics. With cobas® pulse system being available in selected countries now and globally by 2023, this collaboration is a major step forward in making accessible and scalable heart health monitoring a reality,” says CEO, MD Juuso Blomster. Our goal with Roche is to integrate the latest technology into everyday medical practice that leads to early detection of cardiac diseases and improved outcomes. “In everyday patient care, often asymptomatic and mild manifestations of atrial fibrillation may go undetected, as it has not been possible to screen every at-risk individual until now. According to studies, individuals with both atrial fibrillation and diabetes are less likely to notice heartbeat irregularities compared to people with atrial fibrillation and no diabetes. There are several risk factors that significantly increase the risk of developing atrial fibrillation, such as hypertension, aging, and diabetes. Atrial fibrillation is the single most important cause of ischemic stroke. Healthcare professionals performing everyday care of diabetes can now with one portable device screen for atrial fibrillation, and help identify individuals who are at increased risk of adverse health outcomes caused by undetected atrial fibrillation. Cobas pulse, the next generation digital health technology by Roche Diagnostics, combines multiple health applications in one device. As announced on January 12 by Roche Diagnostics, a global pioneer in pharmaceuticals and diagnostics, CardioSignal is now available through the recently launched cobas® pulse system, a glucometer for blood glucose monitoring. CardioSignal’s motion sensor technology allows for easy-to-use and reliable detection of atrial fibrillation with just one minute measurement when the device is placed on chest. Smart digital health technologies can enable a transformation of clinical workflows to point of care diagnostics while minimizing the burden to clinical staff. ![]() The goal is to boost diagnostic performance, simplify clinical workflows, and improve patient outcomes by detecting often asymptomatic underlying heart conditions in everyday care. With this collaboration, CardioSignal’s motion sensor technology for heart disease detection is made available for healthcare professionals by combining it with Roche’s blood glucometer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |